Wells Fargo analyst Stan Berenshteyn lowered the firm’s price target on Health Catalyst (HCAT) to $5 from $6 and keeps an Equal Weight rating on the shares. The firm notes that Q3 slightly beat on one-offs, while 2025 was reaffirmed. Wells is “a bit more cautious” on 2026 EBITDA, but still sees meaningful progression.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT:
- Health Catalyst: Buy Rating Affirmed Amid Strong Financial Performance and Promising Future Prospects
- Health Catalyst price target lowered to $3.25 from $3.50 at Citi
- Health Catalyst Reports Strong Q3 2025 Performance
- Health Catalyst reports Q3 adjusted EPS 6c, consensus 7c
- Health Catalyst sees Q4 revenue $73.5M, consensus $74.79M